In patients undergoing general anesthesia with planned tracheal intubation , a prospective, randomized, controlled study was conducted to record the occurrence of cough 2 minutes after injection of Sufentanil or Tegilerdine. The cough was graded based on the frequency and duration: Grade I, no cough; Grade II, a single mild cough; Grade III, multiple coughs with duration \<1 second; Grade IV, continuous coughing with a duration \>15 seconds.
Age between 18 and 65 years, 18 ≤ BMI (kg/m²) ≤ 30;
ASA grade I ~ III;
Scheduled elective surgery under general anesthesia with tracheal intubation.
Patients with chronic cough (cough lasting >8 weeks) or asthma;
Patients with a history of allergy to the drugs used during the study;
Patients with severe cardiovascular disease, intracranial lesions, eye lesions, or lung lesions.
Parallel
Tegilerdine
DrugInject Tegilerdine in the induction of general anesthesia
Sufentanil
DrugInject Sufentanil in the induction of general anesthesia
Incidence of choking cough response
Two minutes after administration of the study drugs (Tegilerdine/Sufentanil), any clear coughing action is considered an 'occurrence'.
Grading of choking and coughing response
Grading based on the number and duration of coughs: Grade I, no coughing, breathing is even; Grade II, a single mild cough; Grade III, multiple coughs lasting less than 15 seconds; Grade IV, continuous coughing lasting more than 15 seconds
Blood pressure
Blood pressure before and after administration, and before and after intubation
Heart rate
heart rate before and after administration, and before and after intubation
Adverse reaction
such as respiratory depression, vomiting, nausea, itching, etc.)
Click on the lead sponsor to view all of their trials.
